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Histidyl-tRNA synthetase (HARS) ligates histidine to cognate tRNA molecules, which is required
for protein translation. Mutations in HARS cause the dominant axonal peripheral neuropa-
thy Charcot-Marie-Tooth disease type 2W (CMT2W); however, the precise molecular mech-
anism remains undefined. Here, we investigated three HARS missense mutations associated
with CMT2W (p.Tyr330Cys, p.Ser356Asn, and p.Val155Gly). The three mutations localize to the
HARS catalytic domain and failed to complement deletion of the yeast ortholog (HTS1). Enzyme
kinetics, differential scanning fluorimetry (DSF), and analytical ultracentrifugation (AUC) were
employed to assess the effect of these substitutions on primary aminoacylation function andover-
all dimeric structure. Notably, the p.Tyr330Cys, p.Ser356Asn, and p.Val155Gly HARS substitu-
tions all led to reduced aminoacylation, providing a direct connection between CMT2W-linked
HARS mutations and loss of canonical ARS function. While DSF assays revealed that only one of
the variants (p.Val155Gly) was less thermally stable relative to wild-type, all three HARSmutants
formed stable dimers, as measured by AUC. Our work represents the first biochemical analysis of
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CMT-associated HARSmutations and underscores how loss of the primary aminoacylation func-
tion can contribute to disease pathology.
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sory neuropathy, histidyl-tRNA synthetase
1 INTRODUCTION
With a prevalence of one in 2,500 individuals, Charcot-Marie-Tooth
disease (CMT; also referred to as hereditary motor and sensory neu-
ropathy) represents the most common inherited neuromuscular dis-
order. CMT disease is a heterogeneous group of peripheral neu-
ropathies mainly characterized by muscle weakness and sensory loss
in the distal extremities (Skre, 1974). Several subtypes of CMT have
been described, including one form (CMT1) with primary Schwann
cell pathology resulting in demyelination and decreased motor nerve
conduction velocities (MNCVs), a second form (CMT2) with normal
MNCVs but reduced amplitudes of muscle action potentials arising
from axonal degeneration, and an intermediate form that has charac-
teristics of both CMT1 and CMT2 (Dyck & Lambert, 1968; Pareyson &
Marchesi, 2009a; Pareyson&Marchesi, 2009b; Pareyson, et al., 2009).
CMT typically presents in an axon-length-dependent manner with the
structures innervated by longer axons affected first. CMT specifically
affects the extremities, causing progressive muscle weakening and
wasting, decreased sensation, and skeletal deformities. The onset and
penetrance of CMT is variable, withmany patients experiencing symp-
toms in the first two decades of life. At the current time, there are no
effective treatments for CMT.
Over 80 genes have been linked to CMT, distributed among diverse
functional categories (Timmerman, Strickland, & Zuchner, 2014). Four
genes account for the majority of CMT cases, consisting of peripheral
myelin protein 22 (PMP22), myelin protein zero (MPZ), and gap junc-
tion beta-1 (GJB1), which are linked to CMT1, and mitofusin 2 (MFN2),
which is linked to CMT2. In addition to myelin assembly, the diverse
cellular processes affected by CMT include cytoskeleton/axonal trans-
port, protein synthesis and quality control, endosomal sorting, mito-
chondrial function, channel abnormalities, andmRNA/processing tran-
scription (Bird, 1993; Jerath&Shy, 2015).While theend result ofCMT-
associated mutations involves impaired Schwann cell or axon dysfunc-
tion, the precise mechanisms by which alterations of individual genes
bring about these phenotypes is, for many genes, not well understood
(Stum et al., 2011; Timmerman et al., 2014).
Among the genes linked to CMT are the aminoacyl-tRNA syn-
thetases (ARSs), which attach amino acids to cognate tRNAs in the
first step of translation (Antonellis & Green, 2008; Ibba & Soll, 2000).
As essential protein synthesis factors, ARSs are present in all king-
doms and are ubiquitously expressed in all tissues. The human nuclear
genome contains 37 ARS genes, of which 17 encode for a cytoplas-
mic synthetase, 17 encode for a mitochondrial synthetase, and three
encode for bi-functional enzymes that charge tRNA in both cellular
compartments. Interestingly, 31 ARS genes have been implicated in
myriad dominant and recessive human disease phenotypes (Meyer-
Schuman & Antonellis, 2017; Oprescu, et al., 2017). Many of the dis-
eases linked to ARS mutations are severe, recessive developmental
syndromes that affect multiple organs and tissues, including the cen-
tral nervous system (Frohlich et al., 2017; Simons et al., 2015; Zhang
et al., 2014). The majority of the disease-associated mutations have
a clear loss-of-function effect, which is supported by the associated
patient phenotype. For example, many ARS-associated recessive dis-
eases are specific to mitochondrial ARS enzymes and lead to clear
defects in the synthesis of electron transport chain protein synthesis
and thusmitochondrial ATP output (Abbott, Francklyn, & Robey-Bond,
2014).
To date, five genes encoding a cytoplasmic or bi-functional ARS
enzyme have been implicated in autosomal dominant CMT dis-
ease: glycyl-(GARS; MIM# 600287), tyrosyl-(YARS; MIM# 603623),
alanyl-(AARS; MIM# 601065), histidyl-(HARS; MIM# 142810), and
tryptophanyl-tRNA synthetase (WARS; MIM# 191050) (Jordanova
et al., 2006; Latour et al., 2010; Safka Brozkova et al., 2015; Tsai et al.,
2017;Vester et al., 2013).Methionyl-tRNAsynthetase (MARS) variants
have been identified in patients with peripheral neuropathy (Gonzalez
et al., 2013; Hirano et al., 2016; Hyun et al., 2014; Nam et al., 2016).
However, these variants were identified in single individuals or small
families deeming the findings inconclusive. The first ARS implicated in
CMT disease was GARS, where mutations were implicated in axonal
CMT disease via positional cloning in families with an atypical disease
presentation (Antonellis et al., 2003; Sivakumar et al., 2005). Notably,
the majority of patients presented with an upper limb predominant
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neuropathy that affected the intrinsic muscles of the hand (Antonellis
et al., 2003; Sivakumar et al., 2005). Subsequently, YARS, AARS, HARS,
and WARS mutations were identified in families with a more typical
presentation of CMT disease (Jordanova et al., 2006; Latour et al.,
2010; Safka Brozkova et al., 2015; Tsai et al., 2017; Vester et al., 2013).
HARS is unusual among the ARS in that different mutations in the
gene encoding the cytoplasmic enzyme lead to two distinct inherited
neurological syndromes. Initially, a singleHARSmutation (P.Tyr454Ser)
in the homozygous state was linked to recessive Usher Syndrome
Type 3B in a small number of Amish children presenting with early
onset loss of auditory and visual function (Puffenberger et al., 2012)
(Abbott et al., 2017). Initial characterization of the mutant enzyme
did not reveal a significant loss of aminoacylation, change in expres-
sion level, or change in intracellular localization. Subsequently, a can-
didate gene screen of 363 patients with CMT disease and no other
previously acknowledged existing disease-causing alleles identified a
HARS missense mutation (R137Q) in a single patient with peripheral
neuropathy (Vester et al., 2013).Moredefinitive evidence linkingHARS
mutations to CMT disease was provided by the identification of multi-
generational pedigrees with inherited peripheral neuropathy that seg-
regated with HARS missense mutations (T132I, P134H, D175E, and
D364Y) (Safka Brozkova et al., 2015). While previous studies demon-
strated consequences of HARSmutations consistent with pathogenic-
ity, biochemical analyses on the primary function of HARS have yet to
be performed.
Here, we report detailed biochemical analyses of HARS missense
mutations identified in three families with autosomal dominant CMT
disease. As part of our study, eachmutant protein was expressed, puri-
fied, and characterized biochemically. The results indicate that each
of the three mutations leads to a clear reduction in HARS catalytic
activity. These findings provide the first indication that a substantial
decrease in HARS catalytic activity is associated with CMT disease.
The results are discussed in light of currentmodels linking altered ARS
activity to CMT pathophysiology.
2 MATERIALS AND METHODS
2.1 Clinical and genetic analysis of patients with
peripheral neuropathy
2.1.1 Family 1
We applied whole-exome sequencing to a cohort of index patients
from 82 families with genetically undefined distal hereditary motor
neuropathy for which mutations in the known pathogenic genes had
previously been excluded. The Ethical ReviewBoards of the participat-
ing institutions approved this study. All patients or their legal represen-
tatives signed informed consent prior to enrolment. Blood sampling
and DNA extraction was performed according to standard methods.
The Nextera Rapid Capture Expanded Exome kit (62 Mb) (Illumina,
San Diego, CA, USA) was used for exome enrichment. Subsequently,
the libraries were sequenced on a HiSeq 2500 platform (Illumina, San
Diego, CA, USA). The Burrows-Wheeler Aligner (BWA) tool was used
to perform the sequence alignment to the reference genome (hg19,
UCSC Genome Browser). Variant calling was done with Genome Anal-
ysis Toolkit (GATK)UnifiedGenotyper. For the annotation and filtering,
we used the Clinical Sequence Analyzer andMiner (Wuxi NextCODE).
For further filtering of the data, following criteria were applied: no
occurrence or a frequency ≤0.5% of the variants in public exome
variant repositories (Exome Aggregation Consortium, 1000 Genomes
Project, Exome Variant Server, in-house data); variants with impact on
the encoded protein (missense, nonsense, frame shift, inframe indels,
and splice site variants); read depth ≥7; minimal heterozygous call
percentage ≥20%, minimal homozygous call percentage ≥66%. In
addition, all data were imported and re-annotated into the GENESIS
(gem.app) platform, a Web-based tool for next generation sequencing
data analysis (https://thegenesisprojectfoundation.org/) (Gonzalez
et al., 2015). Patients were evaluated by means of details clinical
examination in combination with nerve conduction studies according
to standardmethods.
2.1.2 Family 2
All family members were studied at Bellvitge's University Hospital.
Detailed neurological evaluation was performed on patients and unaf-
fected subjects. Electrophysiological studies were performed using
standard methods in all subjects. We classified the severity of neu-
ropathy symptoms according to the CMT neuropathy score (CMTNS).
Blood samples were obtained from all family members once informed
consent had been given. Genomic DNAwas extracted from peripheral
blood leucocytes. PMP22, MPZ, MFN, and GJB1 mutations were pre-
viously excluded in the index case. Subsequently, a CMT gene panel
screenwas employed to identify candidate disease-causing variants.
2.1.3 Family 3
The family was evaluated in the University of Iowa CMT Clinic.
Informed consent was obtained from all individuals and the study
obtained the approval of the Institutional Review Board at the Univer-
sity of Iowa. Neurological examination and neurophysiological stud-
ies were performed. The second version of the CMTNS (CMTNSv2)
and CMT Exam Score (CMTESv2) [1] were employed to evaluate neu-
ropathy. The SureSelect Human All Exon 50 MB Kit (Agilent, Santa
Clara, CA, USA)) was used for in-solution enrichment, and the HiSeq
2500 instrument (Illumina) was used to produce 100 bp paired-end
sequence reads. The BWA, Picard, and the GATK were used to align
sequence reads and call variants. These data were imported into GEN-
ESIS (GEM.app) (Gonzalez et al., 2015) for further analysis and filtering
of variants.
The following HARS variants were identified in each of the
three families: c.464T > G; p.Val155Gly (Family 1); c.989A > G;
p.Tyr330Cys (Family 2); and c.1067G > A; p.Ser356Asn (Family 3).
HARS variant nomenclature for nucleotide and amino acid changes
are based on accession numbers NM_002109.5 and NP_002100.2,
respectively. The three HARS variants were submitted to ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/) under the accession numbers
SCV000611612 (p.Val155Gly), SCV000611613 (p.Tyr330Cys), and
SCV000611614 (p.Ser356Asn).
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F IGURE 1 Histidyl-tRNA synthetase CMT variants are found in the active site of the dimeric enzyme. A: Histidyl-tRNA synthetase forms a
homodimer (first monomer yellow and second monomer blue). The neuropathy-associated HARS residues are shown in the 3D structure as red
sticks of the HARS dimer bound to histidine (green spheres) (PDB 4PHC). B: The HARS active site pocket (yellow) reveals that neuropathy-
associated mutations face into the active site (shown as red sticks and spheres). C: Modeling in HARS neuropathy-associated substitutions indi-
cates that interference with substrate binding (histidine green sticks and ATP gray sticks) can occur. ATP was modeled into the active site of the
humanHisRS bound to histidine (PDB 4PHC) by aligning the HisRS E. coli structure bound to ATP (PDB 1KMN)
2.2 Computational assessment of HARSmutations
HARS protein sequences were collected from the NCBI Protein
Database (https://www.ncbi.nlm.nih.gov/protein/) for the indicated
species using the following accession numbers: human (Homo sapi-
ens, NP_002100.2), mouse (Mus musculus, NP_032240.3), worm
(Caenorhabditis elegans, NP_001023373.1), yeast (Saccharomyces cere-
visiae, EDN61168.1), and bacteria (Escherichia coli, NP_289067.1).
Multiple-species amino-acid sequence alignments were generated
using Clustal Omega software (Larkin et al., 2007) and annotated
with quaternary structural information by ENDscript (Robert &
Gouet, 2014). Rendering of human HARS 3D protein structures and
neuropathy-associated substitutions was performed by use of PYMOL
using the coordinates corresponding to the structures of apo and his-
tidine bound human cytosolic HARS (PDB IDs: 4PHC and 4 × 5O). The
modeling of ATP into the active site of the humanHARS-histidine com-
plex was performed by aligning this structure to the E. coli HARS-ATP
complex (PDB 1KMN) using the Ce_align subroutine in PyMol. PyMol
sessions of the aligned structures are available upon request. The PDB
IDs used in this study include: 4PHC (Figure 1); 4 × 5O (Figure 2A);
4 × 5O and 1KMN; (Figure 2B); 4 × 5O and 1KMN (Figure 2C); 4 × 5O
and 4PHC (Figure 2D); 4 × 5O (Figure 2E); and 4 × 5O and 1KMN
(Figure 2F).
2.3 Yeast complementation assays
Yeast complementation assays to study the functional consequences
of HARS mutations were generated and performed as previously
described (Vester et al., 2013). Each indicated missense variant
was modeled in the yeast HARS ortholog HTS1 or in the human
HARS open-reading frame (primers available upon request). After
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F IGURE 2 Molecular interactions of HARS neuropathy-associated amino-acid residues in the active site.A: S356 is positioned in the active site
to coordinate a critical arginine residue R388 in motif 3. B: R388 is highly conserved and corresponds to R311 in E. coliHisRS structure (cyan) that
is responsible for positioning the 𝛾 phosphate of ATP adjacent R121.C: Y330 is situated 2.5 Å from the alpha carbon of histidine (green) but makes
no immediate interactions with modeled ATP (gray sticks and spheres).D: Y330 and Y331 facilitate hydrogen bonding interactions with histidine.
Y330 in the apo enzyme (shown as purple sticks) can flip away from the active site and swing 8 Å upon histidine binding (shown as red sticks) to
facilitate hydrogen bonding interactions. E: Phe 171 forms a stacking interaction with the ribose ring of ATP (as modeled in the active site as gray
sticks and spheres). F: p.Val155Gly is buried in the active site and does not mediate any direct interactions with either substrate histidine or ATP,
but in the apo enzyme forms a CH–𝜋 interaction with the aromatic ring of Phe 171within the active site
mutagenesis, wild-type (WT) or mutant HARS or HTS1 was cloned
into pRS316 (Pierce et al., 2011), using the QuickChange II XL Site-
Directed Mutagenesis Kit (Stratagene, San diego, CA, USA). Result-
ing expression clones were purified and fully sequenced to confirm
successful mutagenesis and rule out PCR-induced errors. A haploid
ΔHTS1 strain (harboring a maintenance vector to express WT HTS1
and URA3) was transformed with an empty vector (“Empty” in Fig-
ure 3A and B) or the appropriate WT or mutant HTS1 or HARS in
a LEU2-bearing vector and selected on medium lacking uracil and
leucine (Teknova). For each transformation, at least two independent
plasmid preparations were used and at least two colonies from each
plasmid were selected for additional analysis and grown to satura-
tion for 2 days at 37◦C in liquid media lacking uracil and leucine. A
10 𝜇l aliquot of each culture was spotted undiluted or diluted 1:10
or 1:100 in H2O onto plates containing 0.1% 5-FOA (Teknova, Hollis-
ter, CA, USA) or medium lacking uracil and leucine and incubated at
30◦C for 48–72 hr. Survival was determined by visual inspection of
growth.
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F IGURE 3 Neuropathy-associatedHARSmutations result in loss-of-
function in vivo. A: Yeast complementation analysis of HARS variants.
Haploid ΔHTS1 yeast strains were transformed with a vector contain-
ing no insert (“Empty”) or an insert to express wild-type, p.Val155Gly,
p.Tyr330Cys, or p.Ser356Asn HTS1. Two colonies (indicated by “A”
and “B”) from transformations with p.Val155Gly, p.Tyr330Cys, or
p.Ser356Asn HTS1 are shown. Resulting colonies (undiluted, diluted
1:10, or diluted 1:100) were grown on agar plates containing com-
plete media with 0.1% 5-FOA. Note the severe depletion of growth
associated with p.Tyr330Cys and p.Ser356Asn HTS1 in the 1:10 and
1:100 dilutions. B: Similar yeast complementation assays as describe
in A using the human HARS open-reading frame. Haploid ΔHTS1
yeast strains were transformed with a vector containing no insert
(“Empty”) or an insert to express wild-type, p.Val155Gly, p.Tyr330Cys,
or p.Ser356Asn HARS. After transformations, colonies (undiluted,
diluted 1:10, or diluted 1:100) were grown on agar plates containing
completemediawith0.1%5-FOA.Note the severe depletion of growth
associatedwith p.Val155GlyHARS in the undiluted sample and the lack
of growth in the 1:10 and 1:100 dilutions
2.4 Expression and purification of humanHARS
enzymes
Neuropathy-associated HARS mutations p.Ser356Asn, p.Tyr330Cys,
and p.Val155Gly HARS containing plasmids were generated by
QuickChange II Site-Directed Mutagensis (Qiagen, Venlo, Nether-
lands) using the (pCAG/FLAG/RFC/A) plasmid with CAG promoter
and FLAG-tag from GateWay vector Reading Frame Cassette A
as a template (a generous gift from Dr. Robert Jinks) contain-
ing the gene for human WT N-terminal FLAG-tagged HARS. The
following forward and reverse primers were used in the mutage-
nesis reactions for p.Ser356Asn, forward 5′-CCAGCAGCCACAT
TGCCC ACACCCAGG-3′ and reverse 5′-CCTGGGTGTGGGCAATGT
GGCTGCTGG-3′, for p.Tyr330Cys forward 5′-TCACCCCAGTGTA
GCAATCCAGCCCTCGAG-3′ and reverse 5′-CTCGAGGGCTGGATTG
CTACACTGGGGTGA-3′ reverse, for p.Val155Gly 5-GGTTATCCCG
CCGATATCC CTTTGCTATGTGGTAG-3′ and reverse 5′-CTACCAC
ATAGCAAAGGGATATCGG CGGGATAACC-3′. Successful mutage-
nesis of the HARS gene was analyzed by the Advanced Genome
Technology Core sequencing facility at the University of Vermont and
results were validated using Sequencher (Gene Codes Corporation,
AnnArbor,Michigan, USA). HEK293 cells were transiently transfected
with plasmids expressing N-terminal FLAG-conjugated HARS gene for
either WT or neuropathy-associated HARS mutants. Enzymes were
purified by affinity and ion exchange chromatography as previously
described (Abbott et al., 2017). Purified proteins were visualized by on
a 10% SDS-PAGE gel.
2.5 Multiple turnover aminoacylation kinetics
Multiple turnover aminoacylation assayswere performedusing amod-
ified version of the Uhlenbeck-Wolfson assay as previously described
(Abbott et al., 2017; Wolfson, Pleiss, & Uhlenbeck, 1998). Multi-
ple turnover experiments were conducted in a buffer composed of
(50 mM HEPES pH 7.5, 150 KCl, 10 mM MgCl2, 5 mM ß-ME, 2 U/ml
PPiase and 32P-labeled tRNAHis) at a fixed concentration of enzyme
5 nM for WT and (20 nM) for CMT variants with saturating concen-
trations of two of the three substrates. The saturating concentrations
of tRNAHis, ATP, and histidine were 5 𝜇M, 10 mM, and 5 mM, respec-
tively. The variable concentrations of these substrates were 100 nM
to 15 𝜇M, 25 𝜇M to 5 mM, and 1 𝜇M to 5 mM, for tRNAHis, ATP and
histidine, respectively. The concentration ranges tested for themutant
proteins typically employed a twofold to threefold higher final con-
centration for the variable substrate relative to the ranges employed
for the WT protein. Initial rates were typically sampled over the
first minute of the reaction. Reaction products were detected by
radioisotopic imaging on a Phosphor Imaging screen (Bio-Rad Molec-
ular Imager FXTM, Hercules, CA, USA). The concentration of aminoa-
cylated tRNAHis was quantified by comparing the ratio of the relative
amount of aminoacylated A76 (aa) (determined as counts × mm2) to
total radiolabeled product (aa+ A76) according to Equation (1):
[AA − tRNAHis] =
(AAcounts ×mm2)
(AAcounts ×mm2) + (A76counts ×mm2)
× [tRNAHis] (1)
2.6 Differential scanning fluorimetry
The differential scanning fluorimetry (DSF) experiments were carried
out as previously described (Abbott et al., 2017). Briefly purifiedHARS
proteins were incubated with 6× SYPRO orange dye and DSF buffer
(25 mM HEPES pH 7.5, 50 mM KCl) at an enzyme concentration of
10 𝜇M in a 96-well microplate (Costar/Corning, Corning, NY, USA) to
a final volume of 20 𝜇L. Tm values for apo enzymes were determined
for two biological preparations of enzyme in triplicate for a final of
six replicates. Enzymes were also incubated with either 10 mM histi-
dine (n = 5), 5 mM ATP (n = 2), or 10 𝜇M tRNAHis for WT and 20 𝜇M
tRNAHis (n=3) for peripheral neuropathy-associatedHARSmutations.
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Scan rates were initiated at 26◦C and heated at increments of 1◦C
per minute, to 95◦C while fluorescence intensity was measured every
1◦C. We fit the fluorescence data with GraphPad Prism 7 software as
previously described (Abbott et al., 2017) to determine melting tem-
peratures ofHARS neuropathy-associated enzymemutations and sub-
strate complexes.
The melting temperature (Tm), defined as the midpoint of the pro-
tein unfolding transition curve, was determined using the Boltzman
model as previously described (Niesen, Berglund, & Vedadi, 2007).
GraphPad Prism 7 software was used to fit the fluorescence data
(excluding data after maximal fluorescence intensity) to the Equa-
tion (2):
I = A + (B − A)
1 + e(Tm−T)∕C
(2)
2.7 Analytical centrifugation sedimentation
velocity experiments and analysis
Analytical centrifugation experiments were performed as previ-
ously described (Abbott et al., 2017). Briefly, purified enzymes (WT,
p.Tyr330Cys, p.Val155Gly, and p.Ser356Asn) were dialyzed into a
buffer containing 10 mM potassium phosphate buffer, 50 mM KCl,
and no reducing agents. All protein samples were concentrated to
0.3 OD units/ml at 230 nm (0.7 𝜇M). Sedimentation velocity experi-
ments were performed by the Center for Analytical Ultracentrifuga-
tion of Macromolecular Assemblies at the University of Texas Health
Science Center at San Antonio, and conducted at 20◦C, 35 K rpm, in a
Beckman Optima XLI analytical ultracentrifuge using an An60Ti rotor
and standard 2-channel epon centerpieces (Beckman-Coulter, Brea,
CA, USA) andmeasured by UV intensity.
All data were examined with UltraScan-III ver. 3.5, release 2170
(Brookes E., 2006;Demeler et al., 2016) and hydrodynamic corrections
for buffer density and viscosity was estimated to be 1.0019 g/ml and
0.998 cP, respectively. The partial specific volumeofHARS (0.745ml/g)
was estimated by UltraScan from protein sequence analogous using
methods outlined in Laue, Shah, Ridgeway, and Pelletier (1992). Exper-
imental sedimentation data were pre-processed by two-dimensional
spectrum analysis (Brookes, Cao, & Demeler, 2010; Demeler, 2010;
Schuck, 1999) and fitted by the parametrically constrained spectrum
analysis (PCSA), using a straight-line parameterization coupled with a
Monte Carlo approach (Demeler, 2008; Gorbet et al., 2014). The calcu-
lations (Brookes, 2008) were performed on the Lonestar cluster at the
Texas AdvancedComputingCenter at theUniversity of Texas at Austin
and on Comet and Gordon at San Diego Supercomputing Center.
3 RESULTS
3.1 Clinical and genetic analysis of patients with
peripheral neuropathy
3.1.1 Family 1
A three-generation family of Persian-Jewish descent (living in Israel)
was identified with peripheral neuropathy (Figure 4A). Five affected
individuals are present and the family displays an autosomal domi-
nant inheritance pattern with male-to-male transmission. The age of
onset was in the second decade of life for the two youngest individu-
als, but the age of onset was less clear for the older individuals. In all
cases, the affected status was clear upon examination. All individuals
display amotor predominant to puremotor phenotypewith clear pyra-
midal features as assessed by brisk reflexes and ankle clonus/Babinski
signs. With one exception, all patients had normal sensory exams. At
least two of the elder individuals have severe weakness necessitat-
ing the use of a cane or a wheelchair; however, the younger individ-
uals are ambulatory. Nerve conduction studies are consistent with a
motor predominant axonal neuropathy. There is some co-morbidity, as
the female patient from the second generation has systemic lupus and
one of the males in the third generation has uveitis, hematuria, and
proteinuria.
Whole-exome sequencing was performed on one affected individ-
ual, which revealed common or non-segregating variants in SLC5A7,
SETX, and LAMA2 (the variant in LAMA2 was not consistent with a
dominant neuropathy). This analysis also revealed p.Val155Gly HARS,
which fully segregated with the disease phenotype upon PCR and
Sanger sequencing of additional individuals. Unfortunately, DNA was
not available for the unaffected individual in the third generation.
p.Val155Gly HARS affects an amino-acid residue found in the catalytic
domain of the HARS enzyme (Figure 1A–C) and that is conserved from
human to yeast (Figure 5). p.Val155Gly HARS has not been previously
reported nor has it been detected in the gnomAD database (Table 1)
(Lek et al., 2016).
3.1.2 Family 2
A two-generation pedigree was identified with peripheral neuropathy
(Figure 4B). The age of neuropathy onset for both patients was dur-
ing childhood. Both individuals show amotor predominant phenotype,
with distal motor deficit and atrophy, hammer toes, and pes cavus.
Both affected patients have mild sensory symptoms in the toes, with
reduced vibration sense at the knees. Tendon reflexes were brisk in
bothpatients. Themother (patient 1) is restricted to awheelchairwhile
her son (patient 2) walks with difficulty but without aid. The CMTNS
for patient 1 was 22 and 9 for patient 2. The phenotype of patient 1
is likely exacerbated by concomitant diseases (diabetes, chemotherapy
for melanoma, radiculitis secondary to herpes zoster, and Parkinson's
disease). Nerve conduction studies show axonal motor-predominant
neuropathy in both patients.
Targeted gene panel screening in Family 2 (Figure 4B) revealed
two missense HARS variants in cis: p.Ser227Ala and p.Tyr330Cys.
These variants were previously reported as part of a larger study on
CMT disease (Lupo et al., 2016) but the functional consequences of
the mutations were not assessed. Both mutations segregate with the
disease phenotype; however, p.Ser227Alawas deprioritized due to the
number of alleles detected in gnomAD (37 alleles in 282,464 alleles
total) and the lack of conservation of the affected residue (see Fig-
ure 5). p.Tyr330CysHARS affects an amino-acid residue in the catalytic
core of the HARS enzyme (Figure 1B) that is conserved from human to
bacteria (Figure 5). p.Tyr330Cys has not been previously reported
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F IGURE 4 Histidyl-tRNA synthetase mutations identified in three pedigrees with peripheral neuropathy. A–C: Genotyping was performed to
determine if HARS variants segregate with disease status. The pedigree structures of Family 1 (A), Family 2 (B), and Family 3 (C) are shown. Cir-
cles represent female individuals and squares represent male individuals. Shaded symbols represent affected individuals and non-shaded symbols
represent unaffected individuals. Diagonal lines indicate deceased individuals. Genotypes are indicated under each individual where DNA was
available
nor has it been detected in the gnomAD database (Table 1) (Lek et al.,
2016).
3.1.3 Family 3
A simplex pedigree was identified with two unaffected parents and a
single daughter affected with peripheral neuropathy (Figure 4C). The
affected daughter, at 15 years of age, was seen in consultation for diffi-
cultywithwalking.Her earlymilestoneswerenormal includingwalking
with a normal gait at 12months. Shewas physically active as a child and
able to keep up with her peers until the age of 10 years. At 12 years of
age, she noticed she could no longer walk on her heels. At∼13 years of
age, she developed difficulties with walking. This progressed and she
had problems with other activities such as jumping and running by the
age of 15 years. She had ankle weakness, a foot drop, and right knee
pain. She began to wear foot orthotics bilaterally. No problems with
hand function were reported, but a slight hand tremor was reported
and observed. Her sensory exam was normal to pinprick, light touch,
and joint position sense in all four extremities. Vibration sensationwas
alsonormalwith theexceptionof a slight reductionather toes.Her feet
turned in bilaterally but could be brought to a neutral position. She had
high arches and atrophy noted in her hands and distal forearms. Her
CMTNS (Burns et al., 2012) was a 10, which is in the high end of the
mild range. Her CMT Pediatric Score (Shy et al., 2005) was a 33, which
is in themoderately impaired range.
Whole-exome sequencing was performed on the affected daugh-
ter in Family 3 (Figure 4C), which revealed p.Ser356Asn HARS as the
only candidatedisease-associatedvariant. Sanger sequencing revealed
that this variant was inherited from the unaffected mother suggest-
ing decreased penetrance or that this is a non-pathogenic variant.
p.Ser356AsnHARS is also found in the active site of the HARS enzyme
(Figure 1B andC) and that is conserved fromhuman to yeast (Figure 5).
p.Ser356Asn HARS has not been previously reported; however, it has
been detected in the gnomAD database (five alleles in 277,222 chro-
mosomes; Table 1) (Lek et al., 2016).
TABLE 1 HARS variants identified in patients with peripheral neuropathy
Amino-acid changea Detection in gnomADb dbSNP accession no. Position in yeast HTS1c Reference
p.Thr132Ile Not detected None p.Thr131Ile Safka Brozkova et al. (2015)
p.Pro134His Not detected None p.Pro133His Safka Brozkova et al. (2015)
p.Arg137Gln 20 / 246,154 rs191391414 p.Arg136Gln Vester et al. (2013)
p.Val155Gly Not detected None p.Val154Gly This study
p.Asp175Glu Not detected None p.Asp174Glu Safka Brozkova et al. (2015)
p.Tyr330Cys Not detected None p.Tyr330Cys This study
p.Ser356Asn 5 / 277,222 rs144322728 p.Ser370Asn This study
p.Asp364Tyr Not detected None p.Asp378Tyr Safka Brozkova et al. (2015)
aHuman amino-acid positions are relative to GenBank Accession number NP_002100.2.
bhttps://gnomad.broadinstitute.org.
cYeast amino-acid coordinates correspond to GenBank accession number EDN61168.1.
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F IGURE 5 Neuropathy-associated HARS mutations are highly conserved. A: Multiple-species protein alignments were generated to assess the
conservation of each affected amino-acid position. Complete amino-acid sequence alignment of human, mouse, worm, yeast, and bacterial HARS
were generatedwithClustalOmega and annotatedwith quaternary structural informationwith ENDscript (Robert&Gouet, 2014). The position of
known functional domains of the HARS protein indicated in blue (WHEP-TRS domain of unknown function), red (catalytic core), and yellow (tRNA
binding domain) and motifs critical for substrate binding are indicated along the top. For each of the three variants, the affected amino acid is
indicated by an * in the HARS protein sequence in multiple, evolutionarily diverse species. Note that strictly conserved residues are highlighted in
red with white lettering while slightly conserved residues across multiple but not all species are red
3.2 The identified HARSmutations affect viability
in yeast complementation studies
To test the functional consequences of the HARS missense variants
described above (p.Val155Gly, p.Tyr330Cys, and p.Ser356Asn), each
variant was introduced into the yeast ortholog HTS1 to model the
effect of the mutation in the context of a eukaryotic cell (Table 1).
Yeast complementation assays were then performed to independently
test each missense change for the ability to support yeast cell growth
compared with WT HTS1 or an empty vector. A haploid yeast strain
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(with the endogenousHTS1 locus deleted and amaintenance vector to
express WT HTS1 and URA3) was transformed with either a pRS315
vector with no insert (“Empty”), a pRS315 vector harboring WT HTS1,
or a mutant version encoding one of the three missense mutations
(p.Val155Gly, p.Tyr330Cys, or p.Ser356Asn). Yeast cells were then
selected on media containing 5-FOA, which is toxic to yeast carry-
ing the URA3-bearing maintenance vector (Boeke, LaCroute, & Fink,
1984). Thus, only yeast cells expressing a functional HTS1 allele from
the pRS315 vector will grow in this assay.
Yeast transformed with a WT HTS1 expression vector demon-
strated significant growth,while those transformedwith an empty vec-
tor did not (Figure 3A), consistent with HTS1 being an essential gene
(Vester et al., 2013). Yeast expressing p.Tyr330Cys or p.Ser356Asn
HTS1 displayed severely depleted, but not ablated, yeast cell growth
(Figure 3A), indicating that these are hypomorphic alleles. In contrast,
p.Val155Gly HTS1 supported yeast cell growth in a manner similar to
WT HTS1 (Figure 3A). Growth at 37◦C did not affect the cellular phe-
notype associated with the above mutations (data not shown). In sum-
mary, our previously employed in vivo yeast complementation assay
demonstrated that p.Val155Gly HTS1 supports growth similar to WT
HTS1, and that S365N and p.Tyr330Cys HTS1 are hypomorphic alleles
in this assay.
The lack of a cellular growth defect associated with p.Val155Gly
HTS1 was surprising given that this mutation segregates with dis-
ease in a three-generation family. One possible explanation for this
discrepancy may be differential effects of p.Val155Gly on the func-
tion of yeast HTS1 compared with human HARS. To explore this pos-
sibility, we attempted to rescue deletion of yeast HTS1 with the full-
length human HARS protein. In yeast complementation assays similar
to those described above, expressing human HARS rescued yeast cell
growthwhile a vectorwith noHARS insert did not (Figure 3B).This con-
firms a similar finding that was recently reported (Lee et al., 2017).
We next mutated the HARS expression construct to harbor the three
missense mutations (p.Val155Gly, p.Tyr330Cys, or p.Ser356Asn) and
found that p.Tyr330Cys and p.Ser356Asn HARS did not support any
yeast cell growth indicating that they are functional null alleles (Fig-
ure 3B). Interestingly, p.Val155Gly HARS supported growth, but in a
manner that is severely reduced compared to WT HARS (Figure 3B).
These data indicate that p.Val155Gly HARS is a hypomorphic allele.
Combined, our in vivo functional analyses indicate that p.Val155Gly,
p.Tyr330Cys, and p.Ser356AsnHARS are loss-of-function alleles.
3.3 Multiple-turnover kinetics identify specific
catalytic deficiencies of HARSmutations
The results of the yeast complementation assays and the location of
these neuropathy-associated HARS mutations in the catalytic domain
raised the possibility that these substitutions compromise catalytic
function. As an initial characterization of catalytic function, the pro-
duction of histidyl-tRNA by each mutant and a WT control was mon-
itored over a ten-minute time course in the presence of saturating
concentrations of all three cognate substrates. In excellent agreement
with the yeast complementation results, the two non-complementing
mutants (p.Ser356Asn and p.Tyr330Cys HARS) generated about 20%


































F IGURE 6 Neuropathy-associated HARSmutations reduce aminoa-
cylation function. Progress curves for aminoacylation of tRNAHis sub-
strates with histidine by wild-type or mutant HARS enzymes under
conditions of excess substrates and limiting enzyme. Reaction condi-
tions utilized saturating substrates (10 mM ATP, 10 mM histidine, and
10 𝜇M tRNAHis) with either wild-type or mutant HARS enzymes. The
progress of the reaction was followed by detection of aminoacylated
32P radiolabeled over time, as described inMaterials and Methods. The
progress curves are color coded as follows: wild-type HARS (black dia-
monds, ⧫); p.Val155Gly HARS (green triangles, ⬧); p.Tyr330Cys HARS
(red circles, ●), and p.Ser356Asn HARS (blue squares, ■). Each point
represents themean of three independent experiments, and error bars
indicate the standard error. Inset, progress curves over the first 60 sec
of the amount of charged tRNAHis generated by WT and p.Val155Gly
HARS in 10 min (Figure 6). Despite its near WT level of product accu-
mulation after 10 min, the initial rate of product formation by the
p.Val155Gly mutant was approximately 50% of the WT protein, indi-
cating that this mutant is at least partially compromised for aminoacy-
lation (Figure 6, inset).
In order to assess the effect of the mutant substitutions on
the recognition of individual substrates, the 32P-tRNA aminoacyla-
tion experiments were repeated under multiple turnover conditions
employing fixed nanomolar concentrations of enzyme and varying sub-
strate concentrations. In the first set of kinetic experiments, aminoa-
cylation wasmonitored in presence of varying concentrations of tRNA
and saturating concentrations of histidine and ATP. This set of exper-
iments showed that, while none of the mutants exhibited an elevated
KM for tRNA
His, p.Tyr330Cys and p.Ser356Asn HARS exhibited nine-
fold and 18-fold reductions (0.6 sec−1 and 0.3 sec−1, vs. 5.4 sec−1 for
WT) in the steady-state kcat for aminoacylation, relative to WT HARS
(Figure 7 and Table 2). By comparison, the p.Val155Gly HARS mutant
exhibited a modest two-fold reduction in kcat (Figure 7 and Table 2).
These results confirm and extend the previous yeast complementation
and product formation assays.
When histidine was the variable substrate and tRNA and ATP were
the fixed concentration substrates, the turnover numbers for each
of the mutants were similar to the values obtained in experiments
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F IGURE 7 Identification of specific catalytic defects in neuropathy-
associated HARS CMT mutants by steady-state kinetics. Multiple
turnover aminoacylation reactions were performed under Michaelis–
Menten conditions of excess substrates and limiting enzyme as
described in Materials and Methods. Initial velocity of product forma-
tion was plotted against substrate concentration for A, tRNA; B, his-
tidine, and C, ATP. Fits to the Michaelis–Menten equation returned
kcat and KM values, which are reported in Table 2. The plots are color
coded as in Figure 6: wild-typeHARS (black diamonds,⧫); p.Val155Gly
HARS (green triangles, ⬧); p.Tyr330Cys HARS (red circles, ●), and
p.Ser356AsnHARS (blue squares,■).WhenATPwas the variable sub-
strate, none of themutants reached a saturating velocity at the highest
ATP concentration (5 mM). The inset shows linear fits of the V/S data
for the mutants to allow an estimation of kcat/KM. Each point repre-
sents themean of three independent experiments, and error bars indi-
cate the standard error
where tRNA was the variable substrate (Figure 7 and Table 2). The
most significant kinetic differences were seen with the p.Tyr330Cys
and p.Val155Gly HARS mutants. The KM for histidine was elevated
25-fold for p.Tyr330Cys HARS, and at least 86-fold for p.Val155Gly
HARS (Figure 7 and Table 2). These results illustrate that, despite
the fact that p.Tyr330Cys and p.Val155Gly HARS both exhibit deficits
in histidine binding, the activity of the p.Val155Gly HARS mutant
alone can be rescued by elevated concentrations of histidine. Addi-
tionally, these results suggest that the diminished kcat associated with
p.Ser356Asn HARS appears not be linked to a decrease in binding to
histidine.
The final set of steady-state kinetic experiments investigated the
kinetics of aminoacylation under conditions of variable ATP con-
centrations and saturating histidine (10 mM) and tRNAHis (5 𝜇M).
Kinetic experiments for the WT enzyme indicate that, under these
substrate conditions, the KM value for ATP in the aminoacylation
reaction is 44.2 𝜇M (Table 2). This is comparable to the value of
140 𝜇M determined for the S. typhiumurium WT HisRS catalyzed
aminoacylation reaction (De Lorenzo, Straus, & Ames, 1972). Initial
pilot experiments conducted with the mutants indicated that sub-
stantially higher titration ranges had to be employed in order to
accurately determine parameters. Even under these conditions, sat-
urating velocities were not obtained with any of the mutants. How-
ever, plotting the velocities against the concentration of [ATP] yielded
straight lines from which estimates of the second order rate con-
stant V/KM could be obtained (Figure 7C). Relative to WT HARS, all
three mutants showed significant decreases in V/KM for ATP, corre-
sponding to 342-fold for p.Val155Gly HARS, 866-fold for p.Ser356Asn
HARS, and 2,549-fold for p.Tyr330Cys HARS (Table 2). Based on
these results, we conclude that, for all three mutants, a major com-
ponent of the attenuated catalytic activity originates from a signif-
icant increase in KM, for ATP. It is noteworthy that, while we were
unable to achieve saturation at 5 mM ATP, we were able to repro-
duce kcat results with 10mMATP in both the tRNA and histidine titra-
tions (Table 2). In summary, we conclude that the HARS neuropathy-
associated mutations lead to significant decreases in catalytic activity,
typically reflected in decreases in kcat and increases in the KM for ATP
binding.
3.4 DSF reveals one out of three HARSmutations is
unstable and twomutations have substrate binding
defects
DSF is a useful technique that can be used to assess the melt-
ing temperature stabilizing effect of a substrate with respect to an
enzyme, as well as aid in the evaluation of the effect of a poten-
tial pathogenic missense variant on protein structure (Abbott et al.,
2017). Previously, incubation of HARS with saturating concentrations
of the histidine amino-acid ligand raised the thermal shift transition
temperature by seven degrees (Abbott et al., 2017). On the basis of the
kinetic results indicating weaker binding of both histidine and ATP, we
predicted that one or more the mutants would show altered thermal
shift behavior. Thermal shift assays were performed for each combi-
nation of mutant enzyme and substrate. Consistent with the previous























































































































































































































































































































































































































































































































































































































TABLE 3 Thermal stability of neuropathy-associated HARS vari-
ants and substrate complexes
Enzyme Tm (
◦C) 𝚫Tm (◦C)a 𝚫Tm (◦C) b
WT 51.72 ± 0.44*** – –
WT+ histidine 58.75 ± 0.41 7.03 –
WT+ATP 53.76 ± 0.21 2.04 –
WT+ tRNAHis 53.43 ± 0.41 1.71 –
p.Ser356Asn 50.87 ± 0.33 – −0.85
p.Ser356Asn+ histidine 59.17 ± 0.31 8.30 0.42
p.Ser356Asn+ATP 53.12 ± 0.11 2.25 0.64
p.Ser356Asn+ tRNAHis 55.16 ± 0.20 4.29 NA
p.Tyr330Cys 51.72 ± 0.36 – 0
p.Tyr330Cys+ histidine 55.95 ± 0.32 4.23 −2.8
p.Tyr330Cys+ATP 53.85 ± 0.12 2.13 0.09
p.Tyr330Cys+ tRNAHis 55.88 ± 0.29 4.16 NA
p.Val155Gly 48.05 ± 0.39*** – −3.67
p.Val155Gly+ histidine 49.35 ± 0.67 1.30 −9.4
p.Val155Gly+ATP 51.09 ± 0.16 3.04 −2.67
p.Val155Gly+ tRNAHis 53.91 ± 0.26 5.86 NA
Bold values were previously determined (Abbott et al., 2017).
Values reported are the mean± standard error of two independent experi-
ments in triplicate. Values that are significantly different WT to Val155Gly
are indicated as ***P< 0.0001 (extra sum-of-squares F test).
aRelative to the apo form of the same enzyme.
bRelative to the same form ofWTHARS enzyme.
kinetic data, there was an inverse relationship between the KM for his-
tidine of a givenmutant protein and the extent of temperature stability
provided by incubation with histidine in the assay. As seen in Figure 8
and Table 3, p.Ser356AsnHARS exhibited the same extent of stabiliza-
tion by histidine (8.3◦ vs. 7.03◦) asWTHARS, consistentwith its essen-
tially equivalentKM in aminoacylation. By contrast, p.Tyr330CysHARS
and p.Val155Gly HARS exhibited smaller histidine-mediated tempera-
ture shifts (4.2◦ and 1.3◦, respectively) consistent with their substan-
tially increased Michaelis constants for histidine (202.9 and 687.2 𝜇M
fold, respectively).
ForWT HARS, the ATP and tRNA-mediated temperature shifts are
much smaller (2.04◦ and 1.7◦, respectively) than that provided by his-
tidine (Figure 8 and Table 3). In the presence of saturating ATP (5mM),
all three neuropathy-associated mutations had slightly increased∆Tm
values, corresponding to least 2◦C for p.Tyr330Cys and p.Ser356Asn,
and 3◦C for p.Val155Gly (Table 3). In the presence of 20 𝜇M tRNAHis,
all three mutants exhibited 1◦C in ∆Tm increases in stability (Table 3).
Notably, noneof the threemutants showeda significantly alteredmelt-
ing temperature in the presence of eitherATPor tRNA, despite the fact
that all three show substantially reduced apparent second order rate
constants associated with ATP binding (Table 3).
3.5 Analytical ultracentrifugation confirms that
HARS neuropathy-associatedmutations do not disrupt
enzyme dimerization
Previous studies investigating mutations in the GARS gene linked to
CMT have reported that a subset of the mutant substitutions lead to
ABBOTT ET AL. 427














































































F IGURE 8 Differential scanning fluorimetry of neuropathy-associatedHARS enzymes and their interactionswith substrates.A–C: Melting tem-
perature of apowild-type ormutant HARS enzymes determined at a concentration of 10mMWTenzyme (black diamonds,⧫); p.Ser356AsnHARS
(blue squares, ■); p.Val155Gly (green triangles, ⬧); and p.Tyr330Cys HARS (red circles, ●). D–F: Stabilization by histidine was investigated by
incubation of mutant HARS enzymes with 5 mM histidine. Empty symbols represent apo enzymes, while filled symbols represent histidine bound
complexes of p.Ser356Asn HARS (D); p.Val155Gly HARS (E); and p.Tyr330Cys HARS (F). Thermal shift curves are representations of neuropathy-
associatedmutants measured in duplicate
weaker tertiary interactions and thus reduced dimer stability (Nan-
gle, Zhang, Xie, Yang, & Schimmel, 2007). Given the location of the
HARS mutants in the active site, we considered the possibility that
the decreased activity of these mutants might be a consequence of
reduceddimer stability. Toaddress this hypothesis,we subjectedhighly
purified preparations of each of the mutant proteins and a WT con-
trol to sedimentation velocity experiments at various loading concen-
trations. In these experiments, we monitored protein absorbance at
230 nm, allowing the experiments to be performed at concentrations
thatwould be in the range of the equilibriumdissociation constant (Kd)
for the dimer. As shown in Supp. Figure S1, the molar mass distribu-
tions of the WT and mutant proteins were closely similar. For each
mutant, a major species was observed that had a molar mass that was
in excellent agreementwith the dimer formofHARS (Table 4 and Supp.
Figure S1). In none of the mutants was there a detectable amount of
material corresponding to the monomeric form of the enzyme. On the
basis of these results, we conclude that the pathophysiology of these
mutants is unlikely to be the result of a weakened dimeric interface.
4 DISCUSSION
Mutations in five ARS genes were previously implicated in CMT dis-
ease (Jordanova et al., 2006; Latour et al., 2010; Safka Brozkova et al.,
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2015; Storkebaum,2016;Tsai et al., 2017;Vester et al., 2013).A central
question emerging from those studies is the degree to which the CMT
disease is a direct consequence of a loss of canonical ARS function, or
is instead linked to one or more potential secondary functions. In this
article, we describe detailed functional analyses of three HARS muta-
tions linked to CMT. The characterization of these mutants showed
that they all displayed losses in catalytic activity when assessed in
vivo and in vitro. Notably, the extent of decrease in catalytic activity
correlated with the loss of ability to support yeast growth. The most
active of the three mutants (p.Val155Gly HARS) was the only one of
the three mutants that retained some ability to support yeast growth
when studied in the human HARS open-reading frame. In contrast to
previous work analyzing ARSmutants linked to CMT, eachmutant was
fully characterized with respect to defects associated with recogni-
tion of each substrate; indeed, biochemical analysis of CMT-associated
HARS mutations has not been previously reported. The novel finding
emerging from our analysis is that all three mutants displayed sub-
stantially elevated Michaelis constants for ATP, and two of the three
(p.Tyr330Cys and p.Val155Gly) displayed an elevated KM for histidine.
Notably, none of the three exhibited an altered KM for tRNA. Collec-
tively, these mutants represent some of the best-characterized exam-
ples of ARSs where specific defects in substrate recognition that pro-
duce reduced aminoacylation function are specifically linked to CMT.
It would therefore be valuable to know if other CMT-associated ARS
mutations lead to similar alterations in substrate interactions, as such
information would help develop comprehensive models to explain the
gene-disease relationships.
4.1 Strength of the evidence implicating the newly
identified HARSmutations in neuropathy
Implicating ARS mutations in peripheral neuropathy requires data
showing that the variants segregate with disease in large pedigrees
and are absent at high frequencies in the general population. Indeed,
the majority of previously implicated ARS mutations meet these
criteria (Oprescu et al., 2017). When genetic data are impossible to
obtain, functional studies can be employed to predict pathogenicity,
provided that the functional assays are informative. With respect to
ARSmutations, enzyme kinetic and yeast complementation assays are
informative for predicting mutational pathogenicity (Oprescu et al.,
2017). Several independent lines of evidence allow us to conclude
that p.Val155Gly and p.Tyr330Cys HARS are the causal mutations in
Family 1 and Family 2, respectively. Notably, the mutations segregate
with the CMT phenotype in pedigrees (albeit in a small family for
p.Tyr330Cys), occur at highly conserved amino acids, are absent from
variant databases, and result in loss-of-function effects similar to
other CMT-associated ARS variants. By contrast, the evidence for the
role of p.Ser356Asn in the CMT phenotype in Family 3 is less con-
vincing. Specifically, the patient's unaffected mother is heterozygous
for p.Ser356Asn HARS, and this variant is present (albeit at a very
low frequency) in the gnomAD variant database. However, the fact
that p.Ser356Asn affects a highly conserved amino-acid residue and
displays impaired function similar to validated, disease-associated
ARS mutations strongly supports the conclusion that it may be a
pathogenic variant (Safka Brozkova et al., 2015; Vester et al., 2013).
One possibility is that p.Ser356Asn HARS has reduced penetrance
similar to certain GARS mutations (Sivakumar et al., 2005). This pro-
posal is supported by the low frequency of validated, CMT-associated
ARS mutations in the gnomAD variant database (e.g., p.Gly240Arg
GARS; https://gnomad.broadinstitute.org/variant/7-30649345-G-C;
Gly240Arg is equivalent to p.Gly294Arg on a longer protein isoform).
Conversely, it is possible that p.Ser356Asn is not the disease-causing
mutation in Family 3 despite the deleterious effect on enzyme
function. Thus, we conclude that p.Ser356Asn HARS is an excellent
candidate for pathogenicity in Family 3, but that further genetic and
phenotypic evidence is required to implicate this variant in CMT
disease.
4.2 Structural justification for activity defects
All three of the amino-acid substitutions analyzed here alter amino
acids located in the catalytic domain, consistentwith their pronounced
effect on aminoacylation. Visualization of these substitutions in the
context of available X-ray structure of human HARS provides insights
into potential structural and functional consequences. While Ser356
does not appear to be involved directly in substrate binding interac-
tions, it may be important for positioning other amino-acid residues
within the active site that are critical for binding of the ATP substrate.
ATP binding in the active site of HARS is dependent on magnesium
ions that are coordinated to the non-bridging oxygens of the 𝛽 and 𝛾
phosphates of ATP, and the strictly conserved glutamate in Motif 2. In
the human HARS histidine complex (no ATP), Ser356 is within 2.5 Å
of Arg 388 (Figure 2A), the conserved motif 3 arginine that (based
on the E. coli complex) is predicted to interact with the gamma phos-
phate ofATP (Figure2B). Important caveats regarding the likely effects
of p.Ser356Asn are that, firstly, a complex with ATP is not available,
and secondly, that much of the loop between strands B9 and B10 in
which Ser356 residue resides is disordered in the various humanHARS
TABLE 4 PCSA–Monte Carlo results (straight-line parameterization) from sedimentation velocity experiment
Species Molarmass (kDa) D (×10−7 cm/sec2) s (×10−13 sec) f/f0 RMSD
WT 118.5 (111.6, 125.5) 4.54 (4.43, 4.66) 5.67 (5.48, 5.85) 1.44 (1.43, 1.45) 0.0025
p.Val155Gly 122.0 (110.6, 133.5) 4.43 (4.20, 4.65) 5.68 (5.42, 5.94) 1.46 (1.44, 1.49) 0.0032
p.Tyr330Cys 120.6 (116.3, 124.9) 4.52 (4.50, 4.55) 5.74 (5.51, 5.97) 1.44 (1.42, 1.46) 0.0028
p.Ser356Asn 120.0 (110.3, 129.6) 4.41 (4.34, 4.49) 5.57 (5.21, 5.93) 1.48 (1.46, 1.49) 0.0034
Values in parenthesis are 95% confidence intervals from the Monte Carlo analysis. The theoretical molar mass of HARSWT dimer is 114.9 kDa, indicating
the observed species is a dimer. The residual mean square deviation (RMSD) of the fit is shown in units of absorbance at 230 nm.
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structures, and has different conformations in the different subunits
of the asymmetric unit (Koh et al., 2014). Hence, it is difficult to make
definitive conclusions about the potential role of Ser356 in stabilizing
interactions in the bound complex, and about the consequences of sub-
stitution with asparagine. In any event, the elevated KM for ATP seen
with p.Ser356Asn could be seen as a likely outcome of a local disrup-
tion of contacts to the gamma phosphate.
The one mutant that would be predicted to have the most severe
consequence for HARS function is p.Tyr330Cys, which substitutes a
highly conserved tyrosine in the His A motif that constitutes part of
the binding site for histidine (Figure 5). Notably, this residue has differ-
ent conformations in the apo versus histidine bound human cytoplas-
mic HARS complex. In the apo complex without substrates (4 × 5O),
Y330 adopts a conformation directed away from the active site, point-
ing toward solvent and donating a hydrogen bond to the main chain
carbonyl ofGly108 (Figure 2C). In the complex ofHARSwith its amino-
acid substrate, Y330 moves some 8 Å to approach within 3.1 of the
alpha-carbon of histidine (Figure 2D). In this bound conformation,
Y330 may further stabilize the histidine binding pocket by engaging in
a stacking interaction with the polar group of the neighboring tyrosine
in position 331.
A similar effect may underlie the effect of p.Val155Gly on HARS
function. Notably, this mutant exhibited a lower melting temperature
than the other mutants, but the substitution had no effect on the asso-
ciation constant for the dimer. Analysis of the human HARS–histidine
complex and comparison to the E. coli HisRS–histidinol ATP complex
suggests that p.Val155Gly is unlikely to substitute a residue that inter-
acts directly with ATP (Figure 2E). However, Val155 is in the region of
the active site near where ATP binds, and the valine can potentially
make a CH–𝜋 interaction with the neighboring hydrophobic Phe171
in the active site (Figure 2E). Phe171 in human HARS corresponds to
Phe125 in the E. coli enzyme (Arnez et al., 1995), whichmakes a critical
stacking interaction with the adenine ring (Figure 2F) The substitution
of glycine for valine at position 155 may allow greater conformational
flexibility on the part of Phe171, reducing its ability to generate sta-
ble binding pocket for ATP. The effects of this disruption are apparent
in the elevated KM value for ATP observed for p.Val155Gly. Addition-
ally, a glycine substitution would permit greater conformational free-
dom in the accessible phi-psi angleswithin the peptide backbone of the
beta sheet, potentially accounting for the lowermelting temperature in
the absence of substrate. Furthermore, a less constrained beta sheet
created by the glycine substitution could directly impact the helix 3,
which contains the “TXE” motif for histidine binding. This provides a
structural rationale for the decreased Tm of the p.Val155Gly apo
enzyme, the dramatically reduced Tm in the presence of histidine
(Table 3), and the elevated KM for histidine (Table 2).
4.3 The vast majority of ARSmutations impair
enzyme activity
Previous studies examining the links between mutations in ARS genes
and CMT have addressed the question of whether mutations lead to a
significant loss of aminoacylation activity, or a change in an as yet unde-
termined secondary function. The biochemical analyses in this study
indicate that CMT-linked HARS mutations confer significant reduc-
tions in aminoacylation function, in accordance with what has been
described for AARS mutations (McLaughlin, et al., 2012). These AARS
mutations, like the described HARSmutations, also fail to complement
yeast growth over a backgroundwhere the endogenous yeast gene has
been disrupted (Oprescu et al., 2017). Thus, for AARS and HARSmuta-
tions, the link to CMT appears to be directly associated with a loss of
aminoacylation function.
The link between CMT and reduced ARS function is slightly less
clear for two other ARS genes, GARS and YARS. In these cases, mul-
tiple mutations are linked to the disease, some of which have clear
reductions in aminoacylation, and some of which appear to retain sig-
nificant activity. In GARS, 12 GARS mutations have been associated
with CMT disease, the majority of which are deleterious to enzyme
function (Oprescu et al., 2017). In the case of YARS, two mutants are
reported to have significantly reduced activity (Jordanova et al., 2006)
but one (p.Glu196Lys) appears to be much more active, or even unaf-
fected (Froelich & First, 2011). However, the p.Glu196Lys mutant and
another CMT-associated mutation at the same codon (p.Glu196Gln)
were unable to fully support yeast cell growth in complementation
studies (Gonzaga-Jauregui et al., 2015; Jordanova et al., 2006). Fur-
thermore, studies employing a D. melanogaster model of CMT show
that, despite its near WT activity in vitro, p.Glu196Lys YARS leads to
decreased protein synthesis rates in flies (Niehues et al., 2015). These
and other results suggest that, in the context of specialized cell types,
the consequences of a particular human pathogenic ARSmutationmay
be difficult to predict a priori.Mutations that lead to decreased activity
may have limited phenotypic impact owing to the fact that, under nor-
mal conditions, protein synthesis can be met by less than 100% activ-
ity of a given tRNA synthetase. Conversely, a mutation that has limited
impact on aminoacylation in vitro may exert more deleterious impact
in vivo, owing to folding defects that promote proteotoxic stress. Dis-
crepancies may arise as a consequence of additional interactions with
other proteins and/or RNAs that are necessary to execute all phases of
protein synthesis. Moving forward, a critical question to be addressed
for each CMT-related ARS allele is if protein synthesis is affected as a
direct downstream consequence of impaired aminoacylation.
4.4 Proposed gain-of-function effects of ARS
mutations
Clearly more research is needed to resolve the effect of CMT-
associated ARS mutations on enzyme function. As an alternative
to loss-of-function mechanisms, multiple gain-of-function hypothe-
ses have been proposed, specifically for GARS mutations (Motley, Tal-
bot, & Fischbeck, 2010). For example, a mechanism in which mutant
monomeric GARS binds to the VEGF receptor neuropilin-1 and alters
neuronal signaling has been proposed in the context of a mouse
model (He et al., 2015). As yet, the relevance of this model to human
disease-associated mutations is not fully clear. However, three human
mutant GARS proteins (p.Glu71Gly, p.Leu129Pro, and p.Gly240Arg)
were shown to bind to neuropilin-1 in vitro. Additionally, it was argued
that the propensity of mutant GARS to bind to neuropilin-1 was linked
to weakened dimer formation (Xie, Nangle, Zhang, Schimmel, & Yang,
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2007). While the findings reported here do not explicitly address the
neuropilin-1 hypothesis, our characterization of HARS mutant pro-
teins indicates that, despite a loss of canonical catalytic function, there
is no evidence for weakened dimerization (Supp. Figure S1). It should
also be noted that, despite the linkage of over 80 loci to CMT dis-
ease, neithermutations in neuropilin-1 nor in any of the ligands for this
receptor have been identified in patients with CMT disease.
5 CONCLUSIONS
Here, we present data that for the first time link impaired enzyme
activity to HARS-associated peripheral neuropathy. This observation
dictates considerations of how altered tRNA charging might affect
peripheral nerve function. Human peripheral nerve axons can extend
more than a meter in length, and transport of essential proteins to
the cell periphery is essential for maintaining axon function (Giuditta,
Dettbarn, & Brzin, 1968). There is increasing evidence of local protein
translation along axons and at synapses, but the role of ARSs in this
process is still not well understood (Holt & Schuman, 2013). Moving
forward, it will be important to directly test if CMT-associated ARS
mutations alter specific aspects of protein translation. In summary,
additional studies are required to determine if CMT-associated ARS
mutations act via a loss-of-function or gain-of-functionmechanism;we
suggest that these two mechanisms are not mutually exclusive. Our
study presents data that further supports a loss-of-function molecu-
lar pathology and provides key data, newly appliedmethods, and novel
reagents for studying the pathological mechanism of ARS-associated
human disease.
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